The grocer is proud to support students across Ontario by providing nutritious breakfast kits while school is out.Toronto, ON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The holiday season is a time of joy and togetherness. For over 650,000 Ontario students, it also means losing access to the nutritious breakfast programs they rely on at school(1). This year, Metro is stepping in by distributing hand-packed breakfast kits to students across the province, because nutrition doesn’t go on holiday. In Canada, at least o ...

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York. Piper Sandler 37th Annual Healthcare Conference details:Fireside ChatDate ...

KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported preliminary financial results for the second quarter fiscal 2026 ended October 31, 2025. “Revenue is expected to grow by over 50% in the second quarter and continues to exceed our FY26 plan, reflecting sustained commercial momentum as Kestra grows and penetrates the wearable defibrillator market,” said Brian Webster, President and Chief ...

LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company’s Board of Directors. Mr. Richardson brings more than 20 years of strategy and corporate development experience and in the healthcare and investment banking industries to Autolus’ Board. “Autolus has ent ...

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will be participating in a fireside chat and investor one-on-one meetings at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd, 2025. The fireside chat will be hel ...

IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will participate in a fireside chat at the upcoming 37th Annual Piper Sandler Healthcare Conference on Thursday, December 4, 2025 at 8:50 a.m. ET (5:50 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company’s website under Events. ...

Core Points - Adverum Biotechnologies, Inc. is in the process of being acquired by Eli Lilly and Company, with a tender offer price of $3.56 per share in cash and potential additional value through contingent value rights (CVRs) [1][2][9] - The total potential consideration for Adverum shareholders could reach up to $12.47 per share if certain milestones are achieved [1][9] - The tender offer is set to expire on December 8, 2025, and is contingent upon the tender of a majority of Adverum's outstanding shares [2][5] Financial Details - Adverum has issued a promissory note to Lilly for a total of $65 million, of which $40 million has already been advanced, with an additional $25 million due on December 5, 2025 [3][5] - The promissory note carries an interest rate of SOFR plus 10% per annum, with a maturity date of January 22, 2026 [3][5] - If the merger agreement is terminated, all amounts under the promissory note will become due immediately, which could lead to Adverum's bankruptcy due to insufficient liquidity [3][6] Strategic Considerations - The Adverum Board of Directors believes the cash offer provides immediate liquidity and certainty of value, especially in light of potential liquidation risks [3][9] - The board conducted an 18-month review of strategic alternatives, concluding that the offer from Lilly is the best available option for shareholders [3][9] - The CVRs offer an opportunity for shareholders to gain additional value, contingent on the achievement of specified milestones [3][9]

Core Insights - Seer, Inc. announced a significant genome-wide association study (GWAS) published in Nature Genetics, demonstrating the importance of mass spectrometry in validating protein changes and establishing reliable drug targets and clinical biomarkers [1][10] Group 1: Study Overview - The GWAS involved approximately 1,600 blood samples from diverse ethnic backgrounds, with a discovery cohort of 1,260 and a replication cohort of 325, leading to the detection of 5,753 proteins and quantification of 1,980 proteins in at least 80% of participants [2] - Researchers identified 364 protein quantitative trait loci (pQTLs) associated with protein abundance, with 102 of these replicated in the independent cohort, including 35 previously unreported signals [3] Group 2: Methodology and Findings - Traditional affinity-based proteomics can produce erroneous signals due to epitope effects, where genetic variants alter binding sites, leading to false associations between protein expression and genetic variants [4] - The Proteograph's mass spectrometry approach allows for direct measurement of proteins at the peptide level, effectively mitigating confounding effects and confirming true biological changes [5][6] Group 3: Implications for Research and Development - The study emphasizes that mass spectrometry validation is crucial for ensuring the reliability of protein measurements, which can enhance drug discovery and biomarker development by reducing technical noise and increasing the likelihood of clinical success [9][10] - The findings suggest that datasets relying solely on affinity reagents may contain a significant number of false associations, underscoring the need for mass spectrometry validation in genetic association studies [6][7] Group 4: Future Directions - As proteomics integrates with genomics and clinical data, the accuracy of these datasets will be vital for supporting drug targets and translational medicine, positioning Seer to lead in population-scale proteomics [11]

Core Insights - Bicara Therapeutics announced early data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa in combination with pembrolizumab for first-line HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) [1][2] - The results indicate a high overall response rate and a safety profile consistent with the 1500mg dose, supporting ongoing pivotal trials [1][2] Company Overview - Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, with ficerafusp alfa as its lead program [11] - Ficerafusp alfa is a first-in-class bifunctional antibody designed to enhance tumor penetration by targeting both epidermal growth factor receptor (EGFR) and transforming growth factor beta (TGF-β) [9][11] Clinical Trial Data - In the efficacy evaluable population of 30 patients, the objective response rate was 57%, with 50% achieving partial responses and 7% achieving complete responses [6] - The disease control rate was reported at 83%, and complete neutralization of TGF-β1 was observed [6] - Safety findings were consistent with the known safety profile of ficerafusp alfa plus pembrolizumab in R/M HNSCC [6] Upcoming Events - Bicara Therapeutics will present the findings at the European Society for Medical Oncology (ESMO) Asia Congress on December 6, 2025, and will host a conference call and webcast on the same day [1][5][3]

Core Viewpoint - Targa Resources Corp. has entered into a definitive agreement to acquire Stakeholder Midstream, LLC for $1.25 billion in cash, enhancing its midstream infrastructure and cash flow generation capabilities in the Permian Basin [1][10]. Acquisition Details - The acquisition price of $1.25 billion represents approximately 6 times the estimated unlevered adjusted free cash flow for 2026 [10]. - Stakeholder operates natural gas gathering, treating, and processing services, along with crude gathering and storage services, featuring around 480 miles of natural gas pipelines and a processing capacity of approximately 180 million cubic feet per day [2][10]. - Stakeholder's assets are supported by long-term, fee-based contracts across approximately 170,000 dedicated acres, which exhibit low decline rates, ensuring a stable volume profile [2][10]. Financial Impact - Targa anticipates that Stakeholder will generate unlevered adjusted free cash flow of about $200 million annually, with minimal capital needs and low integration costs [3][10]. - The transaction is expected to have a limited impact on Targa's leverage ratio, maintaining it within the long-term target range of 3.0 to 4.0 times [7][10]. Strategic Fit - The acquisition is viewed as a strategic move to enhance Targa's existing operations, leveraging strong relationships with major producers in the region and complementing its sour gas treating and carbon capture capabilities [4][5][10]. - Targa's CEO emphasized that this transaction aligns with the company's strategy to create shareholder value through balance sheet strength and organic growth opportunities [4][5]. Transaction Timeline and Advisors - The completion of the acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2026 [7]. - RBC Capital Markets is serving as Targa's financial advisor, while Jefferies is acting as the exclusive financial advisor to Stakeholder [8].